These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15379657)

  • 1. The regulation of pharmacogenomics-based drugs and policy making.
    Issa AM
    Curr Top Med Chem; 2004; 4(13):1455-60. PubMed ID: 15379657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.
    Lesko LJ; Salerno RA; Spear BB; Anderson DC; Anderson T; Brazell C; Collins J; Dorner A; Essayan D; Gomez-Mancilla B; Hackett J; Huang SM; Ide S; Killinger J; Leighton J; Mansfield E; Meyer R; Ryan SG; Schmith V; Shaw P; Sistare F; Watson M; Worobec A
    J Clin Pharmacol; 2003 Apr; 43(4):342-58. PubMed ID: 12723455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal.
    Salerno RA; Lesko LJ
    Pharmacogenomics; 2004 Jan; 5(1):25-30. PubMed ID: 14683418
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.
    Garrison LP; Carlson RJ; Carlson JJ; Kuszler PC; Meckley LM; Veenstra DL
    Drug Metab Rev; 2008; 40(2):377-401. PubMed ID: 18464050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and regulatory strategies for drug and diagnostic co-development.
    Hinman LM; Carl KM; Spear BB; Salerno RA; Becker RL; Abbott BM; Kelly JF; Mansfield E; Katz RG; Harper C; Day SP; Pacanowski MA; Pignato W
    Pharmacogenomics; 2010 Dec; 11(12):1669-75. PubMed ID: 21142909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory approval for new pharmacogenomic tests: a comparative overview.
    Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
    Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics: history, barriers, and regulatory solutions.
    Blankstein S
    Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory options for pharmacogenetics.
    Melzer D; Zimmern RL; Detmer DE; Ling T
    Pharmacogenomics; 2003 Sep; 4(5):527-30. PubMed ID: 12943461
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enabling pharmacogenomic clinical trials through sampling.
    Warner A; Nelsen A; Bhathena A; Fitzgerald K; Gilardi S; Kelso E; Knoppers B; McLeod HL; Nelson R; Uyama Y; Weisman J; Rudman A
    Pharmacogenomics; 2010 Dec; 11(12):1649-54. PubMed ID: 21142907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
    Frueh FW; Rudman A; Simon K; Gutman S; Reed C; Dorner AJ
    Pharmacogenomics J; 2006; 6(5):296-300. PubMed ID: 16568150
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics: a new clinical or regulatory paradigm? European experiences of pharmacogenomics in drug regulation and regulatory initiatives.
    Prasad K; Breckenridge A
    Drug Discov Today; 2011 Oct; 16(19-20):867-72. PubMed ID: 21920454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generating and weighing evidence in drug development and regulatory decision making: 5th US FDA-DIA workshop on pharmacogenomics.
    Shaw PM; Zineh I
    Pharmacogenomics; 2010 Dec; 11(12):1629-35. PubMed ID: 21142905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).
    Tremaine L; Brian W; DelMonte T; Francke S; Groenen P; Johnson K; Li L; Pearson K; Marshall JC
    Pharmacogenomics; 2015 Dec; 16(18):2055-67. PubMed ID: 26616152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.